Monitor for Phase 1 data from SEP-479 trial in late 2026/early 2027, which could be a catalyst for the stock. The company's cash runway into 2029 provides runway for clinical development, but no immediate financial impact from this announcement.
Price Chart
Executive Summary
Septerna announced the initiation of Phase 1 clinical trials for its oral PTH1R agonist SEP-479 for hypoparathyroidism, with data expected in late 2026 or early 2027. The company also provided updates on its other clinical programs including SEP-631 and its collaboration with Novo Nordisk, while highlighting its cash runway into 2029.
Key Facts
- Company initiated Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism
- Phase 1 trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers
- Data from the trial is anticipated in late 2026 or early 2027
- SEP-631 Phase 1 study demonstrated robust pharmacodynamics with QD dosing
- Company plans to initiate Phase 2b trial in chronic spontaneous urticaria in 2H 2026
- Cash runway expected to support operating plans at least into 2029
- Company has a $195M upfront payment from Novo Nordisk collaboration
Financial Impact
No immediate financial impact disclosed, but advancement of clinical programs could impact future revenue potential
Risk Factors
- Clinical trial results may not meet expectations
- Development timelines may be delayed
- Competition in hypoparathyroidism and urticaria markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152045 |
| Document: d57504d8k.htm | 0001193125-26-152045 |
| Document: d57504dex991.htm | 0001193125-26-152045 |
| Document: 0001193125-26-152045-index-headers.html | 0001193125-26-152045 |
| Document: 0001193125-26-152045-index.html | 0001193125-26-152045 |
| Document: 0001193125-26-152045.txt | 0001193125-26-152045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Press Release | $38.51 $38.69 | ▲ +0.47% | ▲ +0.69% | $38.27 (−0.62%) |
Sep 3, 2026 28d ago | 3 | $36.75 $39.55 | ▲ +7.62% | ▲ +8.83% | $38.27 (+4.14%) |
Aug 25, 2026 5w ago | 8-K | $41.30 $37.68 | ▼ −8.77% | ▼ −8.23% | $38.27 (−7.34%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 10, 2026 7w ago | 8-K | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Aug 10, 2026 7w ago | Press Release | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.00 $37.84 | ▲ +11.29% | ▲ +10.36% | $38.27 (+12.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access